University of Wisconsin–Madison

Category: Dementia Risk, Diagnosis and Early Detection

The Impact of Social Isolation on Dementia Risk in Older Adults

In May 2023, the U.S. Surgeon General, Dr. Vivek Murthy, released an advisory calling attention to the public health crisis of loneliness and social isolation in the U.S. With this widespread issue affecting such a broad population, how does social isolation impact older adults? Dr. Alison Huang joins the podcast to share insights from her study on the relationship between social isolation and the risk of dementia in older adults. Using data from a nine-year National Health and Aging Trends Study (NHATS), she discusses how factors like living alone, limited social networks and reduced activity participation contribute to increased dementia risk.

Guest: Alison Huang, PhD, MPH, senior research associate, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health

Study Shows APOE Gene Affects Hispanic Populations’ Risk of Cognitive Decline Differently to Non-Hispanic Populations

The APOE gene is recognized as a significant genetic risk factor for cognitive decline, with different alleles, like APOE e2, being seen as protective against decline and others, like APOE e4, indicating an increased risk for cognitive decline. However, new studies are looking at whether these trends are universal across different racial and ethnic groups. Dr. Cally Xiao joins the podcast to discuss her study, which focuses on how different APOE alleles affect risk for Alzheimer’s disease within Hispanic populations compared to non-Hispanic populations.

Guest: Cally Xiao, PhD, Project Specialist, Global Alzheimer’s Association Interactive Network, Laboratory of Neuro Imaging, University of Southern California

Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society

The field of biomarkers is advancing quickly, allowing preclinical Alzheimer’s disease to be identified earlier and earlier in a person’s life. As individuals learn they are at risk for Alzheimer’s years or even decades before experiencing cognitive decline, what does this mean for them and for society as a whole? Drs. Emily Largent and Claire Erickson join the podcast to discuss ten key areas, such as healthcare, insurance, and direct-to-consumer testing, that should be addressed to support those at risk for cognitive decline and broader U.S. society as biomarker testing and disclosures become more prominent.

Guests: Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor, University of Pennsylvania Perelman School of Medicine, and Claire Erickson, PhD, MPA, postdoctoral fellow, University of Pennsylvania Perelman School of Medicine

National Efforts To Standardize Brain Scan Data For More Accurate Alzheimer’s Risk Predictions

Dementia Matters Special Series: The National Strategy for Alzheimer’s Disease Data and Research Part 4

Brain imaging is a key tool in Alzheimer’s disease research and diagnoses, allowing scientists to see changes in the brain years, even decades, before an individual experiences symptoms of dementia. The data these images provide researchers with is incredibly useful, leading the National Alzheimer’s Coordinating Center to take up numerous efforts to standardize, unify and share this type of data across the Alzheimer’s Disease Research Centers. Dr. Beth Mormino joins the podcast to discuss the NIA’s SCAN initiative, the new “legacy” data set, and the importance of standardizing MRI and PET scan procedures to predict brain trajectories better.

Guest: Beth Mormino, PhD, assistant professor, Stanford University

Update on Blood Tests for Alzheimer’s Disease

Research in the field of fluid biomarkers is leading to new developments in Alzheimer’s disease identification, including new tests that can predict Alzheimer’s based on biomarkers in blood. Ahead of his keynote address as part of Alzheimer’s Disease & Related Dementias Research Day on April 5, 2022, Dr. Thomas Karikari joins the podcast to discuss his work with these new blood tests, how accurate they are, and what research needs to be done before they are made available for clinical use.

Guest: Thomas Karikari, PhD, assistant professor, University of Gothenburg, University of Pittsburgh

Aging Behind the Wheel: How Driving Behavior Can Identify Preclinical Alzheimer’s Disease

Dementia impacts a person’s ability to complete day-to-day activities like familiar tasks at work or at home. What if we could identify these changes in everyday behaviors early enough to identify preclinical Alzheimer’s disease? That’s what Dr. Sayeh Bayat, an assistant professor at the University of Calgary, looked to find out. Dr. Bayat is the lead author of a recent paper highlighting how driving behaviors such as braking, following the speed limit and the number of trips taken could predict preclinical Alzheimer’s disease. Dr. Bayat joined the podcast to share findings from the paper and discuss some of the ways engineering and machine learning can help us discover more about dementia and aging.

Guest: Sayeh Bayat, PhD, assistant professor, Department of Geomatics Engineering, University of Calgary

Research Suggests Financial Problems an Early Sign of Alzheimer’s Disease

In a recent study, health economist Lauren Nicholas, PhD, found older adults who go on to be diagnosed with dementia are more likely to miss payments on bills as early as six years before a diagnosis. Dr. Nicholas joins the podcast to discuss her research findings, how financial symptoms could be used as early predictors of dementia, signs that may indicate financial trouble due to dementia, and resources for managing your own or a loved one’s finances early.

Guest: Lauren Nicholas, PhD, associate professor, Johns Hopkins Bloomberg School of Public Health

Update on Blood Tests for Predicting Alzheimer’s Disease

Recent developments have introduced a blood-based test that could predict Alzheimer’s disease, with more of these tests currently in development. Dr. Sterling Johnson joins the podcast to discuss the significance and accuracy of these blood tests, as well as the impact it will have on Alzheimer’s disease research and care. 

Guest: Sterling Johnson, PhD, professor of medicine, University of Wisconsin School of Medicine and Public Health

Benefits of an Early Alzheimer’s Disease Diagnosis

For individuals concerned with memory loss, the first few steps for screening and diagnosis can be the most intimidating. Dr. Cynthia Carlsson discusses recent progress in Alzheimer’s disease research, health disparities some groups face with the disease, and advice for individuals and caregivers who have concerns about memory loss.

Guest: Cynthia Carlsson, MD, MS, professor, University of Wisconsin School of Medicine and Public Health, and director, Wisconsin Alzheimer’s Institute

Alzheimer’s Prevention Initiative investigates genetic risk of Alzheimer’s disease

Research data collected from participants around the world has grown our understanding of genetic risk for Alzheimer’s disease. Guest Jessica Langbaum, PhD, is the co-director of the Alzheimer’s Prevention Initiative at Banner Alzheimer’s Institute, which conducts clinical trials in people at high risk for developing Alzheimer’s disease. Langbaum discusses some recent findings in genetic predisposition for Alzheimer’s disease, the psychological consequences of learning one’s risk, and testing interventions to delay or prevent the onset of symptoms. 

Guest: Jessica Langbaum, PhD, Banner Alzheimer’s Institute

Predicting Risk for Alzheimer’s Disease Today and Tomorrow

This episode offers an overview of the current tools doctors use to examine Alzheimer’s disease risk in their patients, as well as new techniques in development. Our guest discusses the science behind risk testing for dementia, as well as the potential for a low-cost risk test.

Guest: Sanjay Asthana, MD, associate dean for gerontology at the University of Wisconsin School of Medicine and Public Health and director at the Wisconsin Alzheimer’s Disease Research Center

DNA Is Not Your Destiny: Genetics and Alzheimer’s Disease Risk

This episode explores genetic risk factors for early- and late-onset Alzheimer’s disease. Host Nathaniel Chin and guest Corinne Engelman discuss the research looking into genetic risk for Alzheimer’s disease and the uncertainty that comes with genetic testing.

Guest: Corinne Engelman, MSHP, PhD, associate professor, Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health

Bonus Episode: Current Research into Frontotemporal Dementia

In this bonus episode, we continue our conversation with Dr. Howie Rosen on Frontotemporal Dementia (FTD). On last week’s episode, Dr. Rosen spoke on the genetic risk factors, trajectories and family caregiving experiences of FTD. Now, our conversation turns to the research looking into how the disease affects self-awareness, biomarkers and early detection, as well as ways people can volunteer for a research study.

Guest: Howard “Howie” Rosen, MD, behavioral neurologist at the University of California San Francisco Memory and Aging Center

Understanding and Managing Frontotemporal Dementia

Frontotemporal dementia (FTD) is a type of dementia caused by degeneration in the temporal and frontal lobes of the brain. Our guest discusses the symptoms, risk factors, prevalence, and course of the disease, along with information on how a doctor diagnoses FTD and what families and caregivers can do after diagnosis.

Guest: Howard “Howie” Rosen, MD, behavioral neurologist at the University of California San Francisco Memory and Aging Center

Early-onset Alzheimer’s Disease: What to Know and What to Expect

People diagnosed with Alzheimer’s disease before the age of 65 are said to have early-onset Alzheimer’s disease. While this diagnosis is rare, the condition is very serious for the patient and their loved ones. Our guest helps define the disease and its symptoms, walks listeners through a diagnosis, and points to unique considerations for patients and their caregivers.

Guest: Susanne Seeger, MD, associate professor (clinical) of neurology, University of Wisconsin School of Medicine and Public Health